Current filters:


1 to 9 of 44 results

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal


PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Santarus and Depomed expand US deal on Glumetza


US drugmakers Santarus (Nasdaq: SNTS) and Depomed (Nasdaq: DEPO) have entered into a new commercialization…

DepomedDiabetesGlumetzaLicensingNorth AmericaPharmaceuticalSantarus

Merck KGaA's Glucophage Powder cleared in UK and France


Merck Serono, the pharmaceutical unit of Germany's Merck KGaA, says that Glucophage powder for oral solution…

FortametGlucophageGlucophage XRGlumetzaMerck KGaAMetformin HclNystatinOralRiomet

Merck & Co signs performance-based contract with CIGNA


US health insurer CIGNA has reached an agreement with drug major Merck & Co that it says is unique in...

FortametGlucophageGlucophage XRGlumetzaJanumetJanuviaMerck KGaAMetformin HclNystatinOralRiometsitagliptinSitagliptin Metformin HCL

1 to 9 of 44 results

Back to top